A paper from 2025 lays out a way to group people who show little response to GLP-1 drugs according to different biological reasons.
Article suggests three categories for patients who don't respond to GLP-1 drugs
Summary
How do researchers propose to classify people who show little response to GLP-1 receptor agonists and what might explain the differences?
The thread discusses a framework that splits non-responders into receptor-level resistance, signaling problems, and secretory deficiencies. Participants share personal experiences that sometimes match one category and sometimes fall outside the described groups. Several note that current tests cannot reliably identify which mechanism applies to any given person. The discussion also touches on whether newer agents could bypass certain resistance types.
What this discussion establishes- Non-response may stem from receptor issues, downstream signaling faults, or reduced natural hormone release
- No routine clinical test yet distinguishes the three proposed types
- Some users report no benefit from one drug but clear progress after switching to another agent
- Secretory-deficiency cases are described as likely to show strong GI effects even at low doses
- More targeted studies on non-responders are called for
One participant states their experience does not match any of the three categories outlined in the paper
Still openWhether GIPR agonists will reliably help the receptor-level resistance group remains untested in prospective trials
Nothing here is advice.
12 replies · 8 people
↳ replying to @CopperFenwick68
I can't do a great job, but the main point is that different reasons can keep people from responding to these drugs, and identifying the reason might eventually let doctors help more of them.
↳ replying to @CopperFenwick68
The paper says that when someone does not respond well it may not mean the drug itself is useless; their body might have receptor problems, signaling problems, or low natural hormone output. Spotting which issue is present could guide a better choice instead of just raising the dose. Right now, though, everyday clinics lack simple tests that can confirm which category someone belongs to.
This is very interesting. Thank you for posting. My own response to tirz has been milder than what many others here report. I seem to match the receptor-level resistance description. Slow steady progress is fine with me, though it feels hard to judge unless I compare six months at a time.
I saw almost no change on tirzepatide for nearly nine months even at the top dose, and I had bad side effects including bloating, nausea, sulfur burps, and fatigue. A couple of months ago I switched to a different combination and have now lost thirty-three pounds. Food noise went away once the second medicine was added. We need more research on non-responders because my case does not seem to fit the categories in the article.
The group with secretory deficiencies from enteroendocrine cell problems might explain why some people get strong stomach side effects even on very low doses. Those same people are said to be good responders once they get the external incretin. The studies so far have focused on type 2 diabetes.
↳ replying to @BrightKettle28
Compromised enteroendocrine cell malfunction. No way anyone repeats it five times quickly.
↳ replying to @PatientAnchor11
Darn it. 😕 I gave it a go but tripped up right at the start of my opening attempt! 😂😂😂
↳ replying to @PatientAnchor11
I managed to say the phrase five times correctly, but I went slowly and was alone. I am not going to attempt saying it quickly five times; that would be pointless. Even the abbreviation is hard to repeat fast.
↳ replying to @BrightKettle28
I did not watch the whole movie. I saw part of it before I got bored and stopped, so roughly fifteen to twenty shades of gray.
Very interesting! Thank you for posting. If I understand it right, the first group with receptor-level resistance might do better on a different drug if tirz did not work. The causes listed include faulty receptor interactions in the pancreas linked to long-term high blood sugar, inflammation, or changes in gene activity.
↳ replying to @GreyWillow80
I read the paper the same way except the authors added many cautions that were left out. They suggested GIPR agonists might help the first group but said this needs proper study first. They also presented the listed causes only as possibilities, not proven explanations.
Add your experience
If you have tried it, this topic is still open. Sign in to reply — it takes a minute.